Life Science Compliance Update

November

2016

November 2016: Life Science Compliance Update

Written by , Posted in November 2016 LSC Update, This Month in Compliance

The full text of the entire issue is now available to our subscribers. If you are a subscriber please log in now. You may also buy this issue by clicking on the button below.


   or   

November 2016 LSCU Cover

Issue Summary

This month pricing and whistleblowers dominate the compliance landscape. We heard a lot about how the Government wants to shift to value based contracts. What we haven’t heard much about is how these types of contracts will impact the established government pricing world. In the feature article this month, Chris Cobourn and Clay Willis of Huron Consulting explore the implications of value based contracts.

On the whistleblower front, we examine the implications of the SEC’s whistleblower guidance and the impact on FCA and FCPA enforcement. Matt Kelly, from Radical Compliance, takes it a step further looking at retaliation, pre-taliation, and whistleblower hotlines.

All this, plus the latest enforcement activities from the SEC, DOJ, OIG and FDA, round out our November issue!


Feature Article

Arrow

Value Based Contracts and Government Pricing – A Cross Functional View
Chris Cobourn, Managing Director and Clay Willis, Director Huron Life Sciences
Abstract

Issue Articles

Arrow

SEC Provides Explicit Whistleblower Guidance – Hunting Season Is Now Open
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Abstract

Arrow

Examining the FY2015 Report on Medicaid Fraud Control Units
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Arrow

GSK & China – The Latest FCPA Settlement Isn’t the End
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer for Life Science Compliance Update
Abstract

Arrow

Tracking Towards a Banner Year for FCPA and FCA Enforcement
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Abstract

Arrow

Retaliation, Pre-taliation, and Whistleblower Hotlines: How Compliance Officers Can Fight the Biggest Challenge They Face
Matt Kelly, Editor & CEO at Radical Compliance
Abstract

Arrow

Are We Seeing the End of OPDP?
Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update
Abstract

Menu Title